Patient In New Rituxan PML Case Had “Complex” History
This article was originally published in The Pink Sheet Daily
Executive Summary
Label warning updated after single death in long-term RA trial.
You may also be interested in...
Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA
Market withdrawal of Genentech's psoriasis drug Raptiva (efalizumab) shows FDA under new leadership acting decisively on drug safety - especially in cases where comparable treatment alternatives exist
Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA
Market withdrawal of Genentech's psoriasis drug Raptiva (efalizumab) shows FDA under new leadership acting decisively on drug safety - especially in cases where comparable treatment alternatives exist
Can A REMS Save Raptiva? Tysabri-Style Program Would Mean Restrictions
Ongoing discussions about a risk management plan for Genentech's Raptiva (efalizumab) may provide an avenue to maintain the psoriasis drug's commercial viability, despite its safety problems